Satellos Bioscience Incの企業情報（従業員数・代表者名など）
最終更新日：2026年8月13日
特色
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
企業情報
| 英文社名 | Satellos Bioscience Inc |
|---|---|
| 本社所在地 | 200 Bay Street, Suite 2800 TORONTO, ON M5J 2J1 CAN |
| 電話番号 | 647 660-1780 |
| 設立年月 | 2021年8月 |
| 代表者名 | Frank Gleeson |
| 業種名 | 医療関連（Health Care） |
| 市場名 | NASDAQ National Market System |
| 従業員数 | 18人 |
| ウェブサイト | https://satellos.com/ |
企業の強みが業績にどのように表れているか、業績情報よりご確認いただけます。
業績情報を見る